Compare Revvity Inc (RVTY) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Value Index Fund ETF — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Vanguard Value Index Fund ETF trades at $220.6 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 15.5× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| RVTY | VTV | |
|---|---|---|
Market Cap | $16.98B | $262.40B |
Volume | 1,456,900 | 3,293,281 |
Sector | Health | — |
52-Week High | $157.36 | $227.51 |
52-Week Low | $82.26 | $182.86 |
Typical Hold Time | 12 Days | 142 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
VTV trades at $220.59, up 1.09% today, with a bearish technical signal overall despite bullish moving averages. The ETF offers a 2.3% dividend yield and has attracted institutional buying, as seen with QRG Capital Management increasing its stake by 14.7% in Q3 2026. Recent news highlights value stocks outperforming growth in 2026, with VTV leading among Vanguard's large-cap offerings.
The outlook for VTV is supported by the rotation into value stocks and its low 0.03% fee, but risks include underperformance versus the S&P 500 over the long term and sensitivity to interest rate changes. Investor sentiment is mixed, balancing value's resurgence against broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
